Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Overview | 9 | 1 |
| Therapeutics Development | 10 | 5 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Stage of Development | 10 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Therapy Area | 11 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Indication | 12 | 3 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Pipeline Products Glance | 15 | 2 |
| Late Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Products under Development by Companies | 17 | 7 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Therapeutics Assessment | 24 | 5 |
| Assessment by Monotherapy/Combination Products | 24 | 1 |
| Assessment by Mechanism of Action | 25 | 1 |
| Assessment by Route of Administration | 26 | 2 |
| Assessment by Molecule Type | 28 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Companies Involved in Therapeutics Development | 29 | 19 |
| AbbVie Inc. | 29 | 1 |
| Aclaris Therapeutics, Inc. | 30 | 1 |
| Advinus Therapeutics Ltd | 31 | 1 |
| Astellas Pharma Inc. | 32 | 1 |
| AstraZeneca Plc | 33 | 1 |
| Chipscreen Biosciences Ltd | 34 | 1 |
| CJ HealthCare Corp. | 35 | 1 |
| Concert Pharmaceuticals, Inc. | 36 | 1 |
| Eli Lilly and Company | 37 | 1 |
| Galapagos NV | 38 | 1 |
| Gilead Sciences, Inc. | 39 | 1 |
| Incyte Corporation | 40 | 2 |
| Nissan Chemical Industries, Ltd. | 42 | 1 |
| Pfizer Inc. | 43 | 1 |
| Portola Pharmaceuticals, Inc. | 44 | 1 |
| Sareum Holdings Plc | 45 | 1 |
| Theravance Biopharma, Inc. | 46 | 1 |
| Vectura Group Plc | 47 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Drug Profiles | 48 | 65 |
| (INCB-039110 + INCB-040093) Drug Profile | 48 | 1 |
| ATI-50001 Drug Profile | 49 | 1 |
| ATI-50002 Drug Profile | 50 | 1 |
| AZD-0449 Drug Profile | 51 | 1 |
| AZD-1480 Drug Profile | 52 | 2 |
| AZD-4205 Drug Profile | 54 | 1 |
| baricitinib Drug Profile | 55 | 7 |
| cerdulatinib Drug Profile | 62 | 4 |
| CS-944X Drug Profile | 66 | 1 |
| CTP-543 Drug Profile | 67 | 1 |
| filgotinib Drug Profile | 68 | 9 |
| INCB-52793 Drug Profile | 77 | 1 |
| itacitinib adipate Drug Profile | 78 | 3 |
| momelotinib dihydrochloride Drug Profile | 81 | 5 |
| NIP-565 Drug Profile | 86 | 1 |
| peficitinib hydrobromide Drug Profile | 87 | 2 |
| PF-04965842 Drug Profile | 89 | 1 |
| PNQ-401 Drug Profile | 90 | 1 |
| PNQ-701 Drug Profile | 91 | 1 |
| ruxolitinib phosphate Drug Profile | 92 | 13 |
| SAR-20347 Drug Profile | 105 | 2 |
| Small Molecules to Inhibit Jak1 for Undisclosed Indication Drug Profile | 107 | 1 |
| Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis Drug Profile | 108 | 1 |
| TD-1473 Drug Profile | 109 | 1 |
| upadacitinib tartrate Drug Profile | 110 | 2 |
| VR-588 Drug Profile | 112 | 1 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Dormant Projects | 113 | 2 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Discontinued Products | 115 | 2 |
| Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Featured News &Press Releases | 117 | 15 |
| Jun 23, 2016: FDA Grants Breakthrough Therapy Designation for Incyte s Ruxolitinib (Jakafi) in Acute Graft-Versus-Host Disease (GVHD) | 117 | 1 |
| Jun 10, 2016: New Phase 3 Data Show Jakafi (ruxolitinib) is Superior to Best Available Therapy in Patients with Polycythemia Vera | 117 | 1 |
| Jun 09, 2016: Baricitinib Significantly Reduces Joint Damage Progression In Rheumatoid Arthritis In Patients Who Do Not Respond To Conventional DMARDs | 118 | 1 |
| Jun 09, 2016: Patient-reported outcomes across phase 3 studies of baricitinib demonstrate statistically significant improvements in physical function and quality of life symptoms in patients with rheumatoid arthritis (RA) | 119 | 2 |
| Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor | 121 | 1 |
| Jun 07, 2016: Results Of Clinical And Patient-Reported Outcomes Data For Baricitinib In Patients With Rheumatoid Arthritis To Be Presented At Annual European Congress Of Rheumatology | 122 | 1 |
| Jun 06, 2016: Five-year Results from Phase 3 Study of Jakafi (ruxolitinib) Show Sustained Overall Survival Benefit in Patients with Myelofibrosis | 123 | 1 |
| Jun 02, 2016: AbbVie To present Data on ABT-494 at the Annual European Congress of Rheumatology | 124 | 1 |
| Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings | 125 | 1 |
| May 25, 2016: FITZROY Phase 2 study with filgotinib in Crohns Disease presented as late breaker at DDW 2016 | 126 | 1 |
| May 24, 2016: Successful completion of End-of-Phase 2 FDA and EMA consultations in rheumatoid arthritis (RA) | 126 | 1 |
| May 19, 2016: Incyte Highlights Jakafi (ruxolitinib) Abstract to be Presented at the 2016 ASCO and EHA Annual Meetings | 127 | 1 |
| May 19, 2016: Concert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata | 128 | 1 |
| May 04, 2016: Concert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata | 129 | 1 |
| May 03, 2016: Parkinson's disease pathogenesis reduced in rat model by a cell-signaling inhibitor drug | 129 | 3 |
| Appendix | 132 | 2 |
| Methodology | 132 | 1 |
| Coverage | 132 | 1 |
| Secondary Research | 132 | 1 |
| Primary Research | 132 | 1 |
| Expert Panel Validation | 132 | 1 |
| Contact Us | 132 | 1 |
| Disclaimer | 133 | 1 |